|
KMID : 1007020120100030112
|
|
Korean Soceity of Osteroporosis
2012 Volume.10 No. 3 p.112 ~ p.118
|
|
|
The Relationship between Wnt Antagonist Genes Polymorphisms and Changes in Production of Osteoprotegerin and Soluble Receptor Activator of NF-kB by Whole Blood Cells after Hormone Therapy
|
|
Park Kyung-Eui
Lee Dong-Ock
Kim Hoon
Ku Seung-Yup
Kim Seok-Hyun
Choi Young-Min
Kim Jung-Gu
|
|
|
Abstract
|
|
|
|
Objectives: To investigate the relationship between single nucleotide polymorphism (SNP)s in Wnt antagonist genes, and production of osteoprotegerin (OPG) and soluble receptor activator of NF-κB ligand (sRANKL) by whole blood cells after hormone therapy (HT) in postmenopausal Korean women. Materials and Methods: The Dkk1 c.318A>G, Dkk2 c.437G>A, Dkk3 c.1003A>G polymorphisms and sFRP3 c.970C>G, sFRP4 c.958C>A, and c.1019G>A polymorphisms, and sFRP5 c.20G>C polymorphisms were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), direct sequencing, and Taqman assay in 75 postmenopausal Korean women receiving estrogen-progestogen therapy. The production of OPG and sRANKL by lipopolysaccharide-stimulated whole blood cells (WBC) before and after HT of 6 months were also measured. Results: Changes in the production of OPG and sRANKL by lipopolysaccharide-stimulated WBC, and in ratios of sRANKLx1,000/OPG after HT of 6 months were not different according to SNPs in Wnt signal pathway genes except Dkk1 c.318A>G SNP. The AA genotype of Dkk1 c.318A>G SNP showed significantly higher changes (p<0.05) in ratios of sRANKLx1,000/OPG compared to other genotypes. There were no significant differences in changes in the production of OPG and sRANKL, and in ratios of sRANKLx1,000/OPG among combined genotypes of sFRP4 c.958C>A, and c.1019G>A polymorphisms after HT. Conclusions: Dkk1 c.318A>G SNP are related with changes in ratios of sRANKLx1,000/OPG in terms of the production of OPG and sRANKL by lipopolysaccharide-stimulated whole blood cells after HT.
|
|
|
KEYWORD
|
|
|
Hormone therapy, Osteoprotegerin, Receptor activator of nuclear factor-kB ligand, Whole blood cell, Wnt antagonist polymorphism
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|